Firebrick Pharma expands into Singapore retail market

Firebrick Pharma (ASX:FRE) is set to launch its Nasodine® Nasal Spray in Singapore in January 2025. The spray will be exclusively available at Guardian pharmacies for the first year. The company has partnered with DKSH Singapore Pte Ltd to handle logistics and customer service, marking a significant step in expanding its market presence.

Firebrick Pharma's strategic expansion and future outlook

Firebrick Pharma Limited has announced the launch of its Nasodine® Nasal Spray in Singapore by January 2025, in partnership with Guardian, the country's largest pharmacy chain. This exclusivity agreement will facilitate the availability of Nasodine in all Guardian pharmacies, including Changi Airport locations, for a year. To support this launch, Firebrick has partnered with DKSH Singapore Pte Ltd for logistics and customer service management. The company aims to expand its market reach from online sales to retail distribution, achieving a significant milestone ahead of schedule. Firebrick continues to pursue its international market strategy, with ongoing sales through Innorini Life Sciences and plans for future launches in other regions like the Philippines. The partnership with DKSH is set to renew annually, barring a three-month prior notice of termination. Firebrick anticipates sales growth in 2025 through this strategic retail expansion.

Executive insights on strategic partnership

The partnership with Guardian is a major milestone for Firebrick Pharma, achieved ahead of our initial target for pharmacy distribution in Singapore.